Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2022

View Archived Issues

New monoglyceride lipase inhibitors identified at Roche

LG Chem discovers diacylglycerol O-acyltransferase 2 inhibitors

Seoul National University Hospital patents triglyceride-lowering peptides

Friedrich-Alexander-University Erlangen-Nuremberg presents mu-opioid receptor agonists

New USP7 inhibitors identified at Shouyao Holdings

Elicio Therapeutics' TLR9 agonist AMP-CpG induces potent immune and antitumoral effects

PF-07038124: a topical PDE4 inhibitor for atopic dermatitis and plaque psoriasis

LNP formulation development and production service launched by eTheRNA Manufacturing

Artelo collaborates with Trinity College Dublin to better understand FABP inhibition in cancer

Flavonoids as nuclear receptor 4A1 ligands for treating rhabdomyosarcoma

Novel NR4A1 antagonists show antitumor activity in syngeneic mouse model of colon cancer

Gain-of-function study identifies T-cell boosters

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...